

Prospective Clinical Study to Evaluate the Accuracy of Pulse Oximeters in Pediatric Patients with Increased Skin Pigmentation

***UCSF-Stanford Center of Excellence
in Regulatory Science and Innovation (CERSI)***

Christopher S. Almond MD, MPH
Professor of Pediatrics (Cardiology)
Stanford University

Financial Disclosures

- None of the study investigators has any relevant financial disclosures
- This project is supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award [Center of Excellence in Regulatory Science and Innovation grant to University of California, San Francisco (UCSF) and Stanford University, U01FD005978] totaling \$677,365 with 60% percent funded by FDA/HHS. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by FDA/HHS, or the U.S. Government.

Stanford Study Team



Desiree Conrad MD, MA
ACHD Fellow



Chandra Ramamoorthy MD
Cardiac Anesthesia



Rebecca Kameny MD
Cardiac ICU/DEI Lead



Rohan Taneja MBA
Research Coordinator



Ryan Pilkington MS
Research Coordinator



Manchula Navaratnam MD
Cardiac Anesthesia



Greg Adamson MD
Cardiac Cath Lab



Christopher Almond MD MPH
Heart Failure/Transplant



Selena Gonzales MPH
Project Manager



Michelle Williams PhD
Health Equity Research

Objectives

1. To review briefly the study design/rationale of the pediatric pulse oximetry study and to provide an update on the status of the pediatric study.
2. To review the baseline characteristics of the study cohort including the distribution of skin pigment using subjective and objective scales
3. To examine the correlation between individual typology angle (ITA) or colorimeter and pigment scales
4. To review some of the challenges and lessons learned from conducting a pediatric study in pulse oximetry.

Objectives


- 1. To review briefly the study design/rationale of the pediatric pulse oximetry study and to provide an update on the status of the pediatric study.**
2. To review the baseline characteristics of the study cohort including the distribution of skin pigment using subjective and objective scales
3. To examine the correlation between individual typology angle (ITA) or colorimeter and pigment scales
4. To review some of the challenges and lessons learned from conducting a pediatric study in pulse oximetry.

BACKGROUND/RATIONALE


- In infants and children, pulse oximetry is widely used to determine whether a patient is adequately oxygenated. Studies suggest that pulse oximetry systematically overestimates the true oxygen saturation in patients with darker skin pigment
- This error—or bias—puts children with darker skin pigment at considerable risk by failing to detect important levels of hypoxemia that drive critical treatment decisions like medications (COVID), hospital admission, ICU transfer, intubation and ECMO.
- Prior studies have understandable limitations r/t their retrospective design:
 1. Use of race/ethnicity as a proxy for skin pigment
 2. Oxygen saturations extracted from the EHR may not be simultaneous (S_pO_2 and S_aO_2) or drawn at steady-state
 3. EHR has limited information on factors like motion artifact, perfusion quality, & temperature difficult that directly impact measurement validity.
- The purpose of this prospective real-world study is to address these limitations

BACKGROUND

2005



2022 (COVID era)



PE Bickler, et al. *Anesthesiology*, V 102, No 4, Apr 2005

Sjoding et al, *NEJM*, 2020

Andrist et al, *JAMA Pediatrics*, 2022 (N=1061)

Ruppel et al, *JAMA Pediatrics*, 2023 (N=774)



STUDY DESIGN

- **Study Design:** Prospective single-center study (now multicenter)
- **Eligibility Criteria:** Non-anemic children age ≤ 21 years with an arterial line where written informed consent obtained from patient or LAR
- **Setting:** Hospitalized children—cardiac catheterization laboratory, Cardiac ICU, Cardiac Operating Room
- **Exposure variables:** skin pigment as measured by the Von Luschan (VL) scale, Monk Skin Tone (MST) scale, Fitzpatrick Scale. Individual typology angle (ITA) as measured by Konica Minolta (CM-700d) and Delfin colorimeters.
- **Outcome variables:** SpO₂ (Masimo RD) and SaO₂ (Radiometer ABL90 Flex)
- **Secondary variables:** perfusion index (PI), age, self-report race/ethnicity, location, carboxyhemoglobin, temperature, diagnosis, medications.
- **Sample Size:** 154 subjects (evenly divided across 4 VL categories, N~38 each)
- **Data Monitoring Committee:** interim look to re-estimate sample size.

The error may be magnified at low perfusion (Bickler et al, UCSF)

Mean bias not evident at $PI < 2$ (red circle) in adult subjects with lighter skin pigmentation as defined by Fitzpatrick 1-2 skin pigment.


Mean bias evident at $PI < 2$ (red circle) in adult subjects with darker skin pigmentation as defined by Fitzpatrick 5-6 skin pigment.



Update on the status of the pediatric pulse oximetry study



Study Timeline

(9/1/2022-8/31/2023)



Trial Enrollment (Year 1)


(9/1/22-8/31/23)



VL Category 4 patients underrepresented in enrollment leading the DMC to expand enrollment to N=312 with goal of 20-40 VL Category 4 patients


Study Timeline

(9/1/2022-8/31/2023)



Study Timeline

(Year 2 Expansion, 9/1/2023-present)



Objectives


1. To review briefly the study design/rationale of the pediatric pulse oximetry study and to provide an update on the status of the pediatric study.
2. **To review the baseline characteristics of the study cohort including the distribution of skin pigment using subjective and objective scales**
3. To examine the correlation between individual typology angle (ITA) or colorimeter and pigment scales
4. To review some of the challenges and lessons learned from conducting a pediatric study in pulse oximetry.

Baseline Characteristics (N=228)


Characteristic	N (%) or Median (range)
Age—years	4.9 years (4 days to 21.8 years)
<2 years	76 (33%)
2-12 years	70 (31%)
12-22 years	82 (36%)
Female sex (%)	114 (50%)
Hispanic/Latino ethnicity (%)	78 (34%)
Race categories (self-reported)	
White	77 (34%)
African American	38 (17%)
Asian	30 (13%)
Hawaiian/Pacific Islander	5 (2%)
Other	75 (31%)
Baseline SpO ₂ <90%	29%
80-89%	16%
70-79%	12%
60-69%	1%

Enrollment by 4 Von Luschan Categories

Von Luschan Scale--Overall (Dorsal Finger)
(N=208)




Self-report as African American
(N=38)




Pediatric Enrollment by Monk Skin Tone Test

Monk Scale—Overall cohort (N=208)



Monk Scale—Self-report African American (N=38)



Among 36 African American children enrolled, >80% had an MST scale ≤ 7

Objectives

1. To review briefly the study design/rationale of the pediatric pulse oximetry study and to provide an update on the status of the pediatric study.
2. To review the baseline characteristics of the study cohort including the distribution of skin pigment using subjective and objective scales
- 3. To examine the correlation between individual typology angle (ITA) or colorimeter and pigment scales**
4. To review some of the challenges and lessons learned from conducting a pediatric study in pulse oximetry.

Spearman correlation Statistics between Pigment Scales in Children

Skin Pigment Scale	Monk Skin Test-10 ρ (Overall)
Von Luschan-36 (DF)	0.89 (0.86 to 0.93)
Von Luschan-4 (DF)	0.86 (0.82 to 0.89)
Fitzpatrick-6 (DF)	0.87 (0.83 to 0.91)

Spearman Correlation between Pigmentation Scale and ITA (Colorimetry) in Children

Skin Pigment Scale	ITA (Colorimetry) Location	<u>Konica Minolta</u> Spearman's ρ (95% CI)	<u>Delfin</u> Spearman's ρ (95% CI)
Von Luschan-36 (DF)	DF	0.72 (0.63 to 0.81)	0.79 (0.72 to 0.86)
Von Luschan-4 (DF)	DF	0.69 (0.50 to 0.78)	0.77 (0.71 to 0.83)
Monk-10 (overall)	DF	0.69 (0.60 to 0.78)	0.76 (0.70 to 0.83)
Fitzpatrick-6 (DF)	DF	0.70 (0.62 to 0.78)	0.76 (0.70 to 0.82)

ITA Categories: (1): ≥ 50 , (2) 26 to 49, (3) -34 to +25, (4) -44 to 35, (5) ≤ -45

Objectives

1. To review briefly the study design/rationale of the pediatric pulse oximetry study and to provide an update on the status of the pediatric study.
2. To review the baseline characteristics of the study cohort including the distribution of skin pigment using subjective and objective scales
3. To examine the correlation between individual typology angle (ITA) or colorimeter and pigment scales
4. **To review some of the challenges and lessons learned from conducting a pediatric study in pulse oximetry.**

#1. Strategies to enhance minority recruitment can be effective

1. Prioritized VL-4 category patients for approaching and enrollment
2. Favored minority concordance b/w investigators & patient/family where possible.
3. Developed a weekly dashboard to track minority recruitment/enrollment
4. Recruited Michelle Williams PhD to the team to identify strategies to enhance minority recruitment
5. Developed a study brochure that is demographically diverse
6. Enhanced communication strategies (i.e., highlight in the introduction that study is *designed to identify racial bias in hopes of addressing it*)
7. Expanded recruitment to include electronic consent (i.e., for families that must work while their child is hospitalized) and hospital-wide.
8. Expanded study to 2 additional sites (Atlanta/Emory, Oakland/UCSF) (i.e., a multicenter study)

Study Expanded to Two Additional Sites

CHILDREN'S HOSPITAL OF ATLANTA (CHOA)

Emory University

PI: Dr. Laura Downey (peds cardiac anesthesia)

Co-PIs: H Bauser-Heaton (cath), M Mills
(CVICU)



OAKLAND CHILDREN'S HOSPITAL

University of California-San Francisco

PI: Dr. April Edwell (Pediatric Intensive Care)

Co-PI: Patrick McQuillen (PICU, Research)



...Other Lessons Learned

Other Challenges	Lesson Learned
2. No widely accepted pigment scale available at study launch	<ul style="list-style-type: none">• Collecting data on 3 common scales for comparison• Collecting ITA data for objective comparison
3. Children's fear of Colorimeter (Konica) b/c it has appearance of large weapon	<ul style="list-style-type: none">• Involved Child Life experts in smaller, non-sedated children
4. Reduce the impact of pre-analytic factors (handling, processing, timing) on SaO2 measurement	<ul style="list-style-type: none">• Used a validated portable blood gas analyzer (Radiometer ABL90 Flex) for all study patients rather than sending to the clinical lab
5. In cardiac OR, oxygen saturations too dynamic to assess reliably, while on CPB, no pulse	<ul style="list-style-type: none">• Shifted enrollment from OR to cath lab and Cardiac ICU.
6. Parents may not be available at the bedside because of need to work or other children	<ul style="list-style-type: none">• Obtained IRB approval for remote consent (Adobe-Sign)

Conclusions

1. The SPOT BIAS study is designed to determine whether racial bias exists in a contemporary FDA-approved oximeter in children across a wide range of ages.
2. The study has enrolled >225 children across 3 children's hospitals to date and is expected to complete enrollment in the coming months
3. The correlation between the Monk Skin Tone Scale and older pigment scales appears reasonably strong. Initial studies suggest pigments scales correlate moderately with ITA values using two colorimeters.
4. While we've encountered a variety of challenges in conducting the study, most have been addressable and should allow us to answer the study question while also helping to inform the design and conduct of future pediatric oximetry studies.

Pediatric Pulse Ox Collaborators

Stanford University/LPCH

- Christopher Almond MD, MPH (PI)
- Chandra Ramamoorthy MD (Co-PI)
- Desirée Conrad MD (Co-I)
- Rebecca Kameny MD (Co-I)
- Greg Adamson MD (Co-I)
- Selena Gonzales (CERSI PM)
- Rohan Taneja (CRC)
- Michelle Williams PhD (Co-I, SHC)
- Ryan Pilkington (CRC)

UCSF-Stanford CERSI

Lawrence Lin, PhD & Nathan Dang, PharmD

DMC

- Stuart R. Lipsitz, Sc.D.
- Kimberlee Gauvreau, PhD

FDA

Office of Regulatory Science and Innovation (ORSI)

- Kristen Sepulveda (UCSF-Stanford CERSI Program Official)
- Rebekah Zinn (FDA-CERSI Program Team Lead)

Center for Devices and Radiological Health (CDRH)

- Michelle Tarver (FDA Co-Lead)
- Malvina Eydelman (Collaborator/Oversight)
- Allison O'Neill (Safety Signal Coordinator)
- Gene Pennello (Statistician)
- Rebecca Torguson (Statistician)
- Rebecca Ward (Epidemiologist)
- Vasum Peiris (Pediatric Cardiologist)
- Damia Jackson (FDA PM)

Thank You!

US Food and Drug Administration

UCSF EquiOx Study Team
Children's Health Care of Atlanta
Oakland Children's Hospital

Patients and their families

